Evidence map›Paper›PMID 37906424›Full record

ArticlePurinergic signalling2025

Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme.

Álisson Coldebella da Silva, Juliete Nathali Scholl, Amanda de Fraga Dias, Augusto Ferreira Weber, Fernanda Bueno Morrone, Olga Cruz-López, Ana Conejo-García, Joaquín María Campos, Jean Sévigny, Fabrício Figueiró and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Álisson Coldebella da SilvaPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600 - anexo, Porto Alegre, CEP 90035-003, RS, Brazil.
Juliete Nathali SchollPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600 - anexo, Porto Alegre, CEP 90035-003, RS, Brazil.
Amanda de Fraga DiasPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600 - anexo, Porto Alegre, CEP 90035-003, RS, Brazil.
Augusto Ferreira WeberPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600 - anexo, Porto Alegre, CEP 90035-003, RS, Brazil.
Fernanda Bueno MorroneLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Olga Cruz-LópezDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, c/ Campus de Cartuja s/n, Granada, Spain.
Ana Conejo-GarcíaDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, c/ Campus de Cartuja s/n, Granada, Spain.
Joaquín María CamposDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, c/ Campus de Cartuja s/n, Granada, Spain.
Jean SévignyDépartement de microbiologie-infectiologie et d'immunologie, Faculté de Médecine, Université Laval, Québec, QC, Canada.
Fabrício FigueiróPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600 - anexo, Porto Alegre, CEP 90035-003, RS, Brazil.
Ana Maria Oliveira BattastiniPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600 - anexo, Porto Alegre, CEP 90035-003, RS, Brazil. abattastini@gmail.com.
Universidade Federal do Rio Grande do Sul · BRInstituto de Investigación Biosanitaria de Granada · ESPontifícia Universidade Católica do Rio Grande do Sul · BRUniversité Laval · CA

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico CNPq/PQ n°302879/2017-0, Battastini AM and CNPq n°406035/2021-0, CNPq/PQ n° 311580/2021-1, Figueiró FConselho Nacional de Desenvolvimento Científico e Tecnológico FellowshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior FellowshipNatural Sciences and Engineering Research Council of Canada NSERC; RGPIN-2016-05867 - J.S
6 · The paper itself

Abstract

Bladder cancer (BC) is the most common cancer of the urinary tract. Bozepinib (BZP), a purine-derived molecule, is a potential compound for the treatment of cancer. Purinergic signaling consists of the activity of nucleosides and nucleotides present in the extracellular environment, modulating a variety of biological actions. In cancer, this signaling is mainly controlled by the enzymatic cascade involving the NTPDase/E-NPP family and ecto-5'-nucleotidase/CD73, which hydrolyze extracellular adenosine triphosphate (ATP) to adenosine (ADO). The aim of this work is to evaluate the activity of BZP in the purinergic system in BC cell lines and to compare its in vitro antitumor activity with cisplatin, a chemotherapeutic drug widely used in the treatment of BC. In this study, two different BC cell lines, grade 1 RT4 and the more aggressive grade 3 T24, were used along with a human fibroblast cell line MRC-5, a cell used to predict the selectivity index (SI). BZP shows strong antitumor activity, with notable IC

Indexed as

Antineoplastic AgentsPurine-Nucleoside PhosphorylaseUrinary Bladder NeoplasmsApoptosisCell Line, TumorCell ProliferationCisplatinHumansAntineoplastic AgentsCisplatinPurine-Nucleoside PhosphorylaseBladder cancerBozepinibNPP1 enzymePurinergic system

Identifiers

PMID37906424
PMCPMC11958895
OpenAlexW4388077918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.